| |
The challenges in cancer research are vast. Find a partner who can help you overcome them. With expertise ranging from small dose-finding studies to large multinational trials, we understand how to take an asset from concept to commercialization. Let’s navigate the path. Together.
Premier Research. Built for Biotech℠
|
|
Today's Big NewsMay 31, 2023 |
| By Nick Paul Taylor More than 20 years after a pre-merger Biogen and Idec independently raised safety concerns about the mechanism, the French drugmaker has presented phase 2 data that suggest its second-generation drug candidate may be safe and effective in multiple sclerosis. |
|
|
|
By Nick Paul Taylor Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor. |
By Annalee Armstrong There are, at this moment, 187 clinical trials for the neurodegenerative disease underway, the highest ever on record, according to a new report from the Alzheimer’s Association. |
By James Waldron PepGen’s plans to get a second oligonucleotide therapy into the clinic have hit a regulatory roadblock courtesy of a clinical hold notice from the FDA. |
By Annalee Armstrong Can CRISPR—a gene editing mechanism born from a bacterium’s antiviral system—be used as an antibiotic? That’s what SNIPR Biome seems to have found in an early study. |
By James Waldron Pity poor Infinity Pharmaceuticals. The cash-strapped company had been relying on a long-planned merger with MEI Pharma to keep it afloat, but now a new potential buyer has thrown this plan into doubt. |
By Max Bayer Precision BioSciences has landed on an ideal patient population for its lead off-the-shelf cell therapy to treat blood cancer, and it’s, well, precise. |
By Andrea Park Despite multiple attempts to put off the start of her 135-month prison sentence after being found guilty on four counts of defrauding investors in blood-testing startup Theranos, the time has come for Elizabeth Holmes to report to prison. |
By Joseph Keenan InSilicoTrials, an Italian company that uses artificial intelligence and other tools for drug development and trials, is partnering with IBSA Group to expand the use of in silico medicine. |
By Nick Paul Taylor Eli Lilly’s self-imposed exile from Twitter is over. Six months after the fake account furor drove it from the site, the Big Pharma has begun to tentatively reengage with the platform, resuming limited posting and advertising on its renamed corporate account while continuing to evaluate its strategy. |
By Kevin Dunleavy Eli Lilly has agreed to pay $13.5 million to end a six-year, class-action lawsuit that alleged the company overpriced its insulin. As part of the settlement, Lilly has agreed to cap out-of-pocket cost its insulin at $35 per month for four years. |
By Ben Adams Novo Nordisk has lit the tinder of a new megablockbuster market with Saxenda and Wegovy as new, branded anti-obesity drugs are set to haul in $44 billion by this decade’s end. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the 20 most influential people in biopharma, plus a topical gene therapy, a new opioid overdose medication, and the rest of the week's headlines. |
|
|---|
|
|
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
